Sangcyte Therapeutics provide a targeted drug delivery system that can enhance medicine to successfully remove blood clots.

They have carefully designed nanoparticles that use the membranes of red blood cells as the starting material and have included a targeting component to ensure direct delivery of the chosen medicine.

They are currently putting together a preclinical data package including several in vivo studies showing the nanoparticles safety and efficacy. We are looking for grants and pre-seed funding to push towards clinical trials.